User profiles for Sai-Hong Ignatius Ou
 | Sai-Hong Ignatius OuUniversity of California Irvine Verified email at uci.edu Cited by 53503 |
[HTML][HTML] Targeting MET in lung cancer: will expectations finally be MET?
The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …
[HTML][HTML] Scientific advances in lung cancer 2015
Lung cancer continues to be a major global health problem; the disease is diagnosed in more
than 1.6 million new patients each year. However, significant progress is underway in both …
than 1.6 million new patients each year. However, significant progress is underway in both …
Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in …
SHI Ou, CH Bartlett, M Mino-Kenudson, J Cui… - The …, 2012 - academic.oup.com
Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the US Food and Drug Administration
for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung …
for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung …
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
K Bergethon, AT Shaw, SH Ignatius Ou… - Journal of clinical …, 2012 - ascopubs.org
Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene
have recently been described in a subset of non–small-cell lung cancers (NSCLCs). Because …
have recently been described in a subset of non–small-cell lung cancers (NSCLCs). Because …
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
…, DP Cassidy, MA Marx, II Rybkin, ML Johnson, SHI Ou… - Cancer discovery, 2020 - AACR
The discovery of MRTX849 provides a long-awaited opportunity to selectively target KRAS
G12C in patients. The in-depth characterization of MRTX849 activity, elucidation of response …
G12C in patients. The in-depth characterization of MRTX849 activity, elucidation of response …
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF …
Background Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements
generally have a progression-free survival of 8–11 months while on treatment with the ALK …
generally have a progression-free survival of 8–11 months while on treatment with the ALK …
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and …
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was …
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was …
[PDF][PDF] Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
SHI Ou, JS Ahn, L De Petris… - Journal of clinical …, 2016 - clf1.medpagetoday.com
Purpose Crizotinib confers improved progression-free survival compared with chemotherapy
in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but …
in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but …
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
…, M Akimov, JA Bufill, C Lee, D Jentz, R Hoover, SHI Ou… - Cancer discovery, 2015 - AACR
Focal amplification and activating point mutation of the MET gene are well-characterized
oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic splice …
oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic splice …